The AML Therapeutics Market in 2026

Acute myeloid leukemia is a fast-moving blood cancer, and the therapeutics built to treat it are just as fast-moving commercially. Grand View Research sizes the global AML treatment market at $3.47 billion in 2024, projecting growth to $6.29 billion by 2030 at a 10.6% compound annual rate. Other vendors scope the category differently: Straits Research puts 2025 at $3.14 billion using a narrower drug-only definition. Neither number is wrong; they simply include or exclude diagnostics, supportive care and off-label use differently, and a business plan that quotes one figure to investors should say which scope it is using.

The growth is not being driven by more patients; AML incidence has been broadly stable. It is being driven by a shift from broad cytotoxic chemotherapy toward mutation-directed regimens that command premium pricing and longer treatment courses. Age-adjusted death rates from AML have fallen roughly 0.9% a year over 2015-2024, and the gap between age groups is stark: the 5-year survival rate sits around 30-40% for patients under 60 but drops below 20% for patients over 60, per Cancer Research UK. That gap is precisely why so much current development targets specific mutations rather than treating AML as one disease.

Why the market keeps growing faster than patient counts

Three forces explain most of the growth curve in the chart above, and each one is worth a line in your plan's market opportunity section rather than a single vague sentence about "rising incidence." First, comprehensive biomarker testing at diagnosis and relapse has become standard of care in most developed-market treatment centres, which routes a growing share of newly diagnosed patients into a mutation-matched therapy rather than generic induction chemotherapy. Second, combination regimens, particularly venetoclax paired with a hypomethylating agent for patients unfit for intensive chemotherapy, have extended treatment duration and therefore lifetime spend per patient compared with older single-agent protocols. Third, older patients, who make up the majority of new AML diagnoses and were historically undertreated because they could not tolerate intensive chemotherapy, are now a viable commercial population for lower-toxicity oral and combination regimens, which materially expands the addressable patient pool without any change in disease incidence.

Who else is building AML therapeutics

A credible business plan positions the company against real approved and pipeline assets, not a generic "market leaders" paragraph. The current approved standard of care is mutation-specific, and that segmentation is your positioning map:

Below that top tier sits a cohort of clinical-stage companies a new entrant is really competing with for capital and trial sites, including Aptose Biosciences, Sunesis Pharmaceuticals, Stemline Therapeutics, Rgenta Therapeutics and Selvita (now part of Ryvu Biosciences). Several of these are, or were, portfolio companies of the Leukemia & Lymphoma Society's Therapy Acceleration Program, a detail worth knowing before you approach that funder, since they will already understand your competitive set.

The practical takeaway for a business plan: define which biomarker-defined patient subgroup you are targeting, name the approved or late-stage standard of care in that subgroup, and be explicit about whether you are pursuing a first-in-class mechanism or a differentiated follow-on. Investors reading an AML plan can spot a vague competitive section within the first paragraph.

Segment the market the way clinicians actually think about it

Market research vendors slice the AML category by therapy type, mechanism of action, route of administration, patient age band, and end-user (hospital versus specialty infusion centre). A business plan should pick the two or three axes that matter for the specific asset, not reproduce the whole taxonomy. The two splits that matter most in practice are frontline versus relapsed/refractory positioning, and fit-versus-unfit-for-intensive-chemotherapy patient stratification, since both determine trial design, comparator arm selection, and eventual label language.

Route of administration is also a real commercial variable in this category: oral targeted agents such as gilteritinib and ivosidenib have materially changed adherence and site-of-care economics compared with infused or inpatient regimens, and an oral asset supports a different, lighter-weight commercial infrastructure argument in a fundraising narrative than an infused one does. If your asset is oral, say so explicitly in the competitive section: it is a genuine differentiator against the older infused standard of care, not a footnote.

Questions Investors and Founders Actually Ask

These are pulled directly from what people search alongside "acute myeloid leukemia therapeutics business plan." Answering them inside the plan itself, not just this page, saves a lot of due-diligence back-and-forth later, and it signals to a reviewer that the founder has already thought through the questions a diligence process would raise anyway.

What is the market size of the acute myeloid leukemia therapeutics industry?

$3.47 billion in 2024 per Grand View Research, growing to $6.29 billion by 2030. Cite the specific vendor and year in your plan; investors who have read three other biotech plans this month will notice if the number is unsourced.

What is the 5-year survival rate for acute myeloid leukemia?

Roughly 31.9% overall according to SEER, with a sharp age split: 30-40% under age 60, under 20% over age 60. That split is the clinical rationale for most current pipeline strategy and belongs in your problem statement, not buried in an appendix.

How much does it cost to develop an AML drug through Phase 1?

Oncology Phase 1 trials average $4.4 million to $4.5 million, or about $45,200 per enrolled patient. Add preclinical IND-enabling work and GMP manufacturing and a realistic seed-to-Phase-1 budget runs $2.5 million to $16 million depending on trial size and whether manufacturing is outsourced or built in-house.

How long does FDA approval take for a leukemia drug?

The FDA has 30 days to place an IND on clinical hold or clear it to proceed. A subsequent NDA or BLA review runs roughly 10-12 months standard, or 6-8 months under Priority Review, measured from submission rather than from company formation.

What funding is available besides venture capital?

Venture philanthropy from the Leukemia & Lymphoma Society's Therapy Acceleration Program, Innovate UK Biomedical Catalyst grants in the UK, and (historically) NIH SBIR/STTR contracts, though that federal programme's authorising legislation lapsed on 1 October 2025 and had not been renewed as of this writing. Build your funding plan around the routes that are actually live when you file it.

What It Actually Costs to Build This Company

Generic "business plan template" cost ranges do not work for a therapeutics company. A restaurant's $50K launch budget and a first-in-human oncology asset's capital requirement are not the same kind of number, and a plan that pretends otherwise will not survive a first investor call. Budget $2.5 million to $16 million (£2.0 million to £12.6 million) to take a company from incorporation through a completed Phase 1 dose-escalation readout.

The width of that range comes down almost entirely to two decisions: whether you build or outsource GMP manufacturing, and whether the Phase 1 trial is a small dose-escalation cohort of 20 patients or a larger expansion cohort pushing toward 40. Neither decision needs to be made on day one, but your plan should show which end of the range you are targeting and why, because an investor reading "$2.5 million to $16 million" with no further detail will assume you have not made the decision at all.

Full Cost Breakdown

• Company formation, IP filing and freedom-to-operate search: $60K-$180K (£47K-£142K)
• Preclinical IND/CTA-enabling package (toxicology, PK/PD, CMC): $1.5M-$4M (£1.18M-£3.16M)
• GMP drug substance/product manufacturing for Phase 1 supply: $500K-$2M (£395K-£1.58M)
• Regulatory affairs and IND/CTA submission consulting: $150K-$400K (£118K-£316K)
• Phase 1 dose-escalation trial (20-40 patients): $4M-$9M (£3.16M-£7.11M)
• Wet-lab space and specialised equipment lease, 12 months: $200K-$600K (£158K-£474K)
• Clinical data management and eTMF software: $50K-$150K (£40K-£118K)
• Founding team salaries pre-Series A, 6-9 FTE, 12 months: $1.2M-$2.7M (£950K-£2.13M)

Funding Routes

Very little of this capital comes from a bank. In the US, most seed-stage AML therapeutics companies stack founder/friends-and-family capital with venture philanthropy: the Leukemia & Lymphoma Society's Therapy Acceleration Program has invested more than $125 million in blood-cancer therapeutics since 2007 through equity co-investment alongside traditional venture capital, and accepts applications on a rolling basis. UK-based sponsors can apply to Innovate UK's Biomedical Catalyst, whose Industry-led R&D grants fund up to £500,000 of early-to-mid-stage work (TRL 2-4) on a non-dilutive basis. Most companies still close a priced seed or Series A round for the remainder; UK Series A oncology deals averaged roughly £30 million in 2025, against £4.2 million average UK seed rounds.

UK founders raising a priced round below the Biomedical Catalyst threshold should also structure the raise to qualify for SEIS and EIS relief, since a UK-incorporated preclinical biotech is exactly the profile HMRC's schemes were built for: high risk, pre-revenue, and years from a liquidity event. SEIS allows individual investors to put in up to £200,000 a year for 50% income tax relief, and EIS allows up to £1 million a year for 30% relief, both with capital gains exemptions on exit. Getting Advance Assurance from HMRC before you start fundraising is worth doing early; investors will ask for it, and a plan without it signals the founder has not raised UK capital before.

On the US side, angel and pre-seed investors will ask whether the company has an active or planned SBIR/STTR application even though the programme's authorising legislation lapsed on 1 October 2025. Note in the plan that you are tracking the reauthorisation status rather than silently omitting a funding route that was, until recently, one of the more common non-dilutive entry points for cancer therapeutics (NCI's FY24 extramural budget allocated $172 million through SBIR and $24 million through STTR before the lapse).

Lab, CRO and Data Infrastructure Checklist

An AML therapeutics business plan needs an operations section that reads like it was written by someone who has actually stood up a lab, not a generic "we will hire staff and lease premises" paragraph. Here is what that section should itemise, with realistic price bands:

• ELN/LIMS platform (Benchling or equivalent): $15K-$60K/year for a small preclinical team, scaling with users and integrations
• Clinical data management (Veeva Vault Clinical or Medidata Rave): $50K-$150K/year once a Phase 1 protocol is active; enterprise multi-year agreements run into the millions at scale, so a startup should budget the lower single-study tier
• Contract research organisation (CRO) for preclinical toxicology and PK/PD: typically the largest line item inside the $1.5M-$4M IND-enabling budget
• GMP contract manufacturing organisation (CMO) for first-in-human drug supply: $500K-$2M depending on modality (small molecule versus biologic/cell therapy)
• BSL-2 wet-lab bench space: $200K-$600K/year for a fitted-out suite in a life-sciences hub, often available on flexible sub-lease terms from an incubator
• Freedom-to-operate and composition-of-matter patent filing: $60K-$180K for initial filings across US/UK/EU jurisdictions
• Clinical trial insurance and indemnity cover: required before first-patient-dosing; typically bundled into the Phase 1 trial budget by the CRO
• Regulatory affairs consultancy for IND/CTA and Orphan Drug Designation filings: $150K-$400K across the pre-clinical-to-Phase-1 window

Most first-time founders underspend on the CRO/CMO relationship and overspend on permanent headcount before there is a protocol to run. A tighter plan keeps the core team at 6-9 FTE through IND filing and leans on outsourced GMP manufacturing and CRO trial operations, which is exactly why the "lean path" figure above sits closer to $2.5 million than $16 million.

Vendor selection matters as much as the budget line itself. A CRO with existing hematology-oncology trial experience will already have relationships with the specific trial sites that recruit AML patients quickly, which shortens enrollment time far more than a marginally cheaper quote from a generalist oncology CRO. The same logic applies to your CMO: ask specifically about their track record manufacturing the modality you are working with, whether that is a small molecule, an antibody, or a cell therapy, since GMP capability does not transfer cleanly across modalities and a mismatched CMO relationship is one of the more common causes of manufacturing-related delay in a first IND filing.

How AML Therapeutics Companies Make Money

This is the section where most first-time biotech business plans go wrong. There is no per-unit product to sell in year one, so a revenue model built around list-price drug sales in year two is not credible and investors will say so. Pre-revenue AML therapeutics companies realise value through three channels, usually in this order:

• Non-dilutive grants and venture philanthropy (LLS Therapy Acceleration Program, Innovate UK Biomedical Catalyst) fund preclinical and early clinical work without touching the cap table
• Milestone-bearing out-licensing or co-development deals, typically struck around a Phase 1 or Phase 2 data readout, are how most clinical-stage AML assets actually generate cash before approval
• Net product sales, split with a commercial partner or sold directly, only arrive post-approval and are the smallest realistic near-term revenue line for a company at business-plan stage

A worked licensing-deal example

A Phase 1-ready AML asset with a validated FLT3 or IDH1/2 mutation-directed mechanism can realistically support a regional out-licensing deal structured as $8 million to $25 million upfront, plus $150 million to $400 million in development, regulatory and sales milestones, plus tiered royalties of 8-14% on net sales if the drug reaches commercialisation. Those figures reflect deal terms seen across recent hematology-oncology licensing transactions for assets at a similar clinical stage; they are not a guarantee, and your plan should present them as a scenario, not a forecast line.

Once a product does reach the market, branded specialty oncology therapeutics typically carry 70-85% gross margins, since manufacturing cost is a small fraction of list price. The financial model your investors actually care about at this stage is the burn-and-runway model: how many months of capital does the current raise buy, and what data does it produce before the next raise or deal needs to close. Build that model before you build a five-year P&L with product revenue in it.

A worked burn-and-runway example

Take a $2.6 million seed raise with a 7-person preclinical team. Fully loaded team costs, lab sub-lease, and outsourced preclinical study fees typically run $150,000 to $190,000 a month at that headcount, which gives roughly 14 to 17 months of runway before a bridge or Series A needs to close. Stack a $500,000-$1.1 million non-dilutive award (LLS Therapy Acceleration Program co-investment or Biomedical Catalyst grant) on top of the same burn rate and the runway extends to 17-24 months, comfortably past an IND filing and into early Phase 1 enrollment. This is the calculation an investor actually runs when they read your plan, so show your own version of it rather than making them reconstruct it from your cost tables.

Where to Base the Company

Location decides which CROs, patent attorneys, regulatory consultants and trial sites you can reach without a long commute, and it shows up directly in your fundraising narrative.

United States: Kendall Square, Cambridge, Massachusetts

Boston-Cambridge anchors the largest concentrated biotech cluster in the world, with more than 1,000 life-sciences companies and 18 of the top 20 global biopharmaceutical companies present in the region. Kendall Square specifically has become synonymous with oncology and RNA-medicine biotech, hosting Takeda Oncology among others. Locating here shortens the distance to CRO partners, GMP contract manufacturers and the specialist patent bar that AML licensing deals depend on, though lab-space costs sit at the top end of the $200K-$600K/year range used earlier in this guide.

United Kingdom: the Golden Triangle (London, Oxford, Cambridge)

The Golden Triangle generates over £8.4 billion a year for the UK economy and employs more than 24,000 life-sciences professionals. Cambridge, Oxford, Imperial College and UCL produced 172 life-sciences spinouts between 2011 and 2021, more than the next ten UK university regions combined, and roughly 75% of all UK life-sciences vacancies sit inside this triangle. It is also where most MHRA ILAP applicants and Biomedical Catalyst grant recipients are already based, which matters for building relationships with reviewers ahead of a submission.

Secondary hubs worth considering

San Diego and the San Francisco Bay Area remain strong US alternatives with lower real-estate pressure than Kendall Square, and both have deep oncology CRO networks. Outside the Golden Triangle, Manchester and Edinburgh are building smaller but genuine life-sciences clusters backed by regional Innovate UK funding, worth a look for founders prioritising cost over density of adjacent biotechs.

Lean-virtual versus lab-based: an honest trade-off

Not every AML therapeutics company needs its own wet lab from day one. A "virtual" model, where the core team is scientific and regulatory leadership and all preclinical work is contracted to a CRO, can shave $200K-$600K a year off the cost structure and lets the founding team sit anywhere with good flight connections to the CRO. The trade-off is speed of iteration: in-house teams inside a cluster like Kendall Square or the Golden Triangle can walk a sample down the hall for an assay result the same afternoon, where a fully outsourced model waits on a CRO's queue. Most seed-stage AML companies land on a hybrid: a small in-house team for assay development and data interpretation, with GMP manufacturing and the Phase 1 trial itself fully outsourced regardless of location.

Regulatory Pathways: FDA, MHRA and EMA

This is not a generic "get a business licence" section. AML therapeutics regulation is genuinely different by jurisdiction, and a plan that treats FDA and MHRA/EMA as interchangeable will be caught out at diligence.

United States (FDA)

• Investigational New Drug (IND) application to FDA's Office of Oncologic Diseases: no filing fee, but FDA has 30 days to place a clinical hold or clear the trial to proceed
• Orphan Drug Designation via the Office of Orphan Products Development: application fee waived (worth over $4.6 million against a future marketing application), plus a 25% tax credit on qualified clinical trial costs; standard review runs about 90 days
• Biologics License Application or New Drug Application: standard FDA review runs 10-12 months, or 6-8 months under Priority Review, from submission
• Market exclusivity: 7 years post-approval under Orphan Drug status, independent of patent protection

United Kingdom (MHRA)

• Clinical Trial Authorisation (CTA): MHRA's statutory review window is 30 calendar days for a standard application
• Innovative Licensing and Access Pathway (ILAP), Innovation Passport: a post-Brexit accelerated pathway coordinating MHRA, NHS England and NICE from early development; reopened for applications 31 March 2025 after a refresh; oncology was the largest single indication category among the first 40 Innovation Passports awarded, at 43%
• Biomedical Catalyst Industry-led R&D grant (Innovate UK): up to £500,000 non-dilutive for early-to-mid-stage work, rolling annual competition cycle

European Union (EMA)

EMA Orphan Drug Designation requires the target condition to affect fewer than 5 in 10,000 people across the EU. AML met this threshold at an estimated 1.3 in 10,000 at the time of designation for several sponsors. The designation grants up to 10 years of market exclusivity, formal protocol assistance from EMA, and reduced regulatory fees. Multiple AML assets, including annamycin, OXC-101, pracinostat and AB8939, have received EMA orphan designation through this route, so it is a well-trodden path rather than a novel strategy for a new entrant to pursue.

Sequencing the three pathways in parallel

The single biggest regulatory-timeline mistake a first-time AML founder makes is treating FDA, MHRA and EMA as a sequence rather than three clocks that can run at once. A well-sequenced plan files the FDA Orphan Drug Designation request as soon as preclinical proof-of-concept data exists, submits the MHRA CTA and, where relevant, an ILAP Innovation Passport application in the same quarter, and prepares the EMA orphan dossier alongside rather than after the US filing. Run sequentially, these three processes can add 6-9 months to a programme that did not need to lose them; run in parallel, most of that time overlaps with the preclinical and manufacturing work you are doing anyway.

Five Mistakes That Sink First-Time AML Founders

None of these are exotic errors. They show up in nearly every first business plan Avvale reviews for a preclinical oncology company, and every one of them is fixable before you send the plan to an investor rather than after a term sheet falls through.

• Budgeting for one trial instead of the full runway. Founders routinely price a Phase 1 trial in isolation and forget the preclinical package, GMP manufacturing and 12 months of team salaries that come before it, then run out of cash mid-enrollment.
• Treating FDA and MHRA/EMA as one process. A 30-day IND review, a 30-day CTA review and a 90-day EMA orphan designation review are not the same clock, and a plan that files sequentially rather than in parallel loses months it did not need to lose.
• Filing for Orphan Drug Designation too late. Waiting for Phase 1 data before applying means missing the tax credit on the trial costs already incurred; the designation is most valuable when filed before the expensive clinical work starts.
• Underinvesting in CMC and manufacturing readiness. Chemistry, manufacturing and controls gaps are consistently the most common cause of clinical hold letters in oncology INDs, yet founders often treat CMO selection as an afterthought behind the science.
• Modelling product revenue instead of licensing-deal economics. A five-year P&L with list-price drug sales in year two misleads early investors about the real path to cash; the credible near-term model is milestone and royalty income from an out-licensing deal, not direct sales.

The common thread across all five is sequencing. Regulatory strategy, manufacturing readiness, and fundraising all move faster when they are planned as parallel workstreams from incorporation rather than as a checklist tackled one item at a time after the science looks promising. A plan that shows the founder has thought through the sequencing, not just the science, reads very differently to an investor who has sat through a hundred biotech pitches.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These visual mockups are generated from the same assumptions used throughout this page, using the same seed-raise and milestone figures set out in the startup-cost and revenue-model sections above so the numbers in your plan are internally consistent rather than pulled from three different assumption sets.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your company at a glance, written to hold an investor's attention for the first 60 seconds
• Company Overview — Legal structure, IP position, location, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory pathway specific to your mechanism
• Competitive Analysis — Approved and pipeline assets in your biomarker-defined subgroup, and where you differentiate
• Funding Strategy — Non-dilutive grants, venture philanthropy, and equity funding sequencing
• Regulatory Plan — IND/CTA timeline, Orphan Drug Designation strategy, and jurisdiction sequencing
• Operations Plan — CRO/CMO relationships, lab infrastructure, and hiring plan through IND filing
• Management Team — Founder bios, scientific advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a milestone-based capital model covering the seed-to-Phase-1 runway, cash flow by quarter, and a startup capital requirements table you can use directly in investor or grant conversations. See also our guidance on adjacent cancer immunotherapy and oncology practice business plans if your programme sits closer to those categories, and our business plan writer service if you want a consultant involved from the first draft.

Frequently Asked Questions

Useful Links & Resources

These links were preserved from the live page so important references and partner links are not lost during the page refresh.

• Facebook
• Instagram
• LinkedIn
• YouTube
• More Avvale client case studies
• Cancer oncology business plan template